About US
Contact us
-
Bayer to pay $110 million to get out from under 500 Yaz lawsuitsThree months of negotiations have apparently resulted in Bayer ($BAYN) deciding that claims against itsYasminline of birth control are worth about $220,000 each. Citing sources,Bloombergreports, the2012/4/16
-
Novartis reports patient taking Gilenya developed rare brain diseaseExpectations for the blockbuster status of Gilenya dimmed today when developer Novartis ($NVS) disclosed that a patient taking the multiple-sclerosis drug has developed a rare brain disease. The c2012/4/16
-
FDA to require prescriptions for farm antibioticsThe FDA will require farmers to get prescriptions for livestock antibiotics under new rules designed to curb development of antibiotic-resistant pathogens. The agency says antibiotics should only be g2012/4/13
-
Roche jeers at Illumina's boasts as proxy fight escalatesAnthropologists could gather plenty of material during a hostile bid. The competing press releases, the public correspondence, the CEO statements--a PhD candidate could spin all that into a respectabl2012/4/13
-
UPDATED: Judge hits J&J with $1.1B penalty in Risperdal caseJohnson & Johnson ($JNJ) has suffered another Risperdal defeat. And this one is several times larger than the others: An Arkansas judge slapped the drugmaker with $1.1 billion in penalties for dec2012/4/12
-
FDA adds clotting data to Bayer's Yaz, YasminBayer's ($BAYRY.PK)Yaz and Yasmin may be linked to a higher risk of blood clots than other contraceptive pills, the FDA said, but then again, they may not be. To make sure doctors and patients are2012/4/12
-
Patients put a high value on cancer meds--and on hopeThere's been a lot of debate about new and expensive cancer drugs. How much is 6 extra months of life worth? A year? The U.K.'s cost-effectiveness agency tries to answer this question with mathematica2012/4/11
-
Should FDA change its rules to prevent another Tricor?The Archives of Internal Medicine has made a run at the Abbott Laboratories ($ABT) fenofibrate saga. After studying years of prescription data, researchers concluded that branded versions of the drug-2012/4/11
-
AstraZeneca investors lobby for management shake-upThe knives are out at AstraZeneca ($AZN). Investors are agitating for big changes at the troubled drugmaker,even asking for a new CEO, the Financial Times reports. Despairing over the company's recent2012/4/10
-
Novartis CEO explains how and why he cut jobsNovartis ($NVS) CEO Joe Jimenez (photo) tells the company's layoff story to Bloomberg. One nugget: He chose to cut jobs "from a position of strength," rather than wait until poor company performance f2012/4/10